Last reviewed · How we verify
Nuron Biotech Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| NU100 | NU100 | phase 3 | S1P1 receptor modulator | S1P1 | Multiple Sclerosis | |
| rhIFN beta-1b | rhIFN beta-1b | phase 3 | Interferon | IFN-beta receptor | Immunology |
Therapeutic area mix
- Immunology · 1
- Multiple Sclerosis · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Active Biotech AB · 1 shared drug class
- Archigen Biotech Limited · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Bayer · 1 shared drug class
- BioLineRx, Ltd. · 1 shared drug class
- Biogen · 1 shared drug class
- Bright Minds Biosciences Pty Ltd · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nuron Biotech Inc.:
- Nuron Biotech Inc. pipeline updates — RSS
- Nuron Biotech Inc. pipeline updates — Atom
- Nuron Biotech Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nuron Biotech Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nuron-biotech-inc. Accessed 2026-06-10.